NCT02761980已完成3 期
A Phase 3, Double-blind, Randomized, Placebo-controlled, Full Factorial, Safety And Efficacy Study Comparing The Antipyretic Effects Of A Single Oral Dose Of Ibuprofen (Ibu) 250 Mg/ Acetaminophen (Apap) 500 Mg Caplets To Ibu 250 Mg And Apap 500 Mg Caplets In Healthy Male Volunteers With Fever Induced By An Endotoxin
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 290
- 试验地点
- 1
- 主要终点
- Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours
研究概览
简要总结
This is a single dose study that will evaluate the efficacy and safety of a Fixed Dose Combination Ibuprofen 250 mg/ Acetaminophen 500 mg tablet in healthy male patients with fever. Results for the Fixed Dose Combination product will be compared to the individual components Ibuprofen 250 mg and Acetaminophen 500 mg and also compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects who, at the time of screening, are between 18 and 55 years of age, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
- •The subject must have a normal, stable body temperature at Screening and on Day
- •If the subject's oral temperature is not between 97.4°F and 98.8°F, then 2 additional oral temperature readings will be obtained within a 30 minute period. These 3 consecutive temperature readings must be between 97.4°F and 98.8°F, with the highest value within 0.4°F of the lowest temperature value.
- •Body Mass Index (BMI) of 17.5 to 37.0 kg/m2; and a total body weight 50 kg (110 lbs) at Screening.
- •The subject has demonstrably adequate veins, by visual inspection, for IV catheter insertion.
排除标准
- •Evidence or history of clinically significant laboratory abnormality, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that may increase the risk associated with study participation.
- •Subjects with any gastrointestinal disorders (eg, gastrectomy, tracheostomy, esophageal surgeries, short gut syndrome, peptic ulcer disease, known or suspected obstructive disease, previous gastrointestinal surgery, felinization of the esophagus, hypomotility of the gastrointestinal track) that could affect the absorption, metabolism, or excretion of the study medication or affect the results of the ingestible thermometer.
- •Subjects at risk for excessive bleeding.
- •Subjects with a history of nasal polyps, angioedema, or significant or actively treated bronchospastic disease.
- •Screening supine blood pressure ≤90 or ≥140 mm Hg (systolic) or ≤50 or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure (BP) is ≤90 or ≥140 mm Hg (systolic) or ≤50 or ≥90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three consecutive BP values should be used to determine the subject's eligibility.
- •Screening supine 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening and on Day 1 prior to RSE administration. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three consecutive QTc or QRS values should be used to determine the subject's eligibility.
- •The subject has a history of recurrent or acute or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc., or those with a positive QuantiFERON Tuberculosis, Hepatitis B surface antigen, Hepatitis C antibody, and/or Human immunodeficiency virus (HIV) test at Screening. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
- •Subjects who have experienced cold/flu symptoms (ie, runny nose, cough, and/or fever) within 2 weeks prior to the first administration of study treatments.
- •Subjects with a reduction in heart rate to ≤50 beats per minute or deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the investigator following a carotid sinus massage procedure.
研究组 & 干预措施
Ibuprofen 250 mg / Acetaminophen 500 mg
Experimental
Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
干预措施: Ibuprofen 250 mg / Acetaminophen 500 mg (Drug)
Ibuprofen 250 mg
Active Comparator
Single dose of 2 caplets of IBU 125 mg by mouth
干预措施: Ibuprofen 250 mg (Drug)
Acetaminophen 500 mg
Active Comparator
Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
干预措施: Acetaminophen 500 mg (Drug)
Placebo
Placebo Comparator
Single dose of 2 caplets of Placebo by mouth
干预措施: Placebo (Drug)
结局指标
主要结局
Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours
时间窗: 0 to 8 hours post-dose
WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours). Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point up to 8 hours (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours).
次要结局
- Time to Return to Normal Body Temperature(Baseline (pre-dose) up to 8 hours post dose)
- Time Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6(0 to 2 hours postdose, 0 to 4 hours postdose, 0 to 6 hours postdose)
- Time to Rescue Medication(0 to 8 hours post dose)
- Time Weighted Sum of Temperature Difference From 6 to 8 Hours(6 to 8 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar LinesGlabellar LinesNCT02493946Ipsen600
已完成
3 期
Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionMotion SicknessNCT04947423Repurposed Therapeutics, Inc.140
撤回
3 期
Study Comparing 3 Formulations to Evaluate the Efficacy and Safety of the Inflammatory Symptoms of the Upper Respiratory Tract, in Children Between 2 and 6 Years OldCommon ColdNCT00967759Ache Laboratorios Farmaceuticos S.A.
终止
不适用
Trial Evaluating Ambulatory Treatment of Travelers' DiarrheaAcute Watery DiarrheaDysentery/Febrile DiarrheaNCT01618591Uniformed Services University of the Health Sciences384
已完成
1 期
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsInflammatory Disorder of the Respiratory TractChronic Obstructive Pulmonary DisorderNCT02307162Verona Pharma plc112